Dr Aldoss on Responses With WU-CART-007 After Enhanced Lymphodepletion in R/R T-ALL/LBL

Ibrahim Aldoss, MD, associate professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses the impact of enhanced lymphodepletion on response rates and infection severity with the allogeneic CAR-T cell therapy WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic leukemia (LBL) in a phase 1/2 trial (NCT04984356).